0001193125-26-115226
SEC filingMereo BioPharma Group plc (MREO) reported FY 2025 revenue of $0.5 million, primarily from limited sources, with cost of revenue at $0.133 million. The company incurred a net loss of $41.9 million, driven by high operating expenses including research and development of $17.8 million and general and administrative costs of $23.0 million, resulting in a loss from operations of $40.1 million. Other factors included foreign currency losses of $6.3 million offset by interest income of $2.2 million and R&D tax credits of $1.9 million. Year-over-year, net cash used in operating activities improved to $31.0 million from $32.8 million in 2024, aided by $3.3 million in R&D tax credits and a $0.5 million milestone payment. Investing activities used minimal $20 thousand net, while financing provided $0.3 million. Balance sheet shows cash and equivalents at $41.0 million, total assets of $45.9 million, and shareholders' equity of $40.9 million with accumulated deficit of $501.0 million. Management indicates existing cash funds operations into mid-2027, amid ongoing clinical development and need for additional funding.
Mereo BioPharma Group plc reported FY 2025 revenue of $500K and cost of revenue $133K. Research and development expenses were $17.8M, general and administrative $23.0M, leading to loss from operations of -$40.1M. Net loss before tax was -$41.9M, with no income tax benefit, resulting in net loss of -$41.9M. Loss per share basic and diluted was -$0, with weighted average shares basic at 797.1M. Total comprehensive loss was -$33.9M after $8.0M foreign currency translation gain. Compared to 2024, operating cash use decreased to $31.0M from $32.8M, investing cash use to $20K from $0.7M, financing to $0.3M from $46.1M. Accumulated deficit reached $501.0M.
Revenue was $500K for FY 2025. No detailed segment breakdown or geographic mix disclosed. Minimal revenue reflects early-stage biotech focus on development rather than commercialization. Other income included $300K, with a $0.5M milestone on leflutrozole noted in cash flow discussion.
No gross profit or margin explicitly stated. Operating loss of $40.1M on $0.5M revenue indicates negative operating margin. High R&D and G&A costs dominate expense structure, consistent with clinical-stage operations. Share-based compensation $7.6M contributed to non-cash adjustments.
Net cash used in operating activities: -$31.0M. Investing: -$20K (purchases of intangibles $300K offset by $300K out-licensing proceeds). Financing: $327K from warrant exercises and share issuances. Cash decreased $30.7M to $41.0M, with $1.9M exchange effect. Total current assets $45.0M, total assets $45.9M. Current liabilities $4.3M, total liabilities $5.0M. Shareholders' equity $40.9M.
Existing cash and equivalents expected to fund committed clinical trials, operating expenses, and capital needs into mid-2027. Continued losses anticipated from R&D on setrusumab, alvelestat, and others. Additional funding required for development, approvals, commercialization. Risks include collaboration performance, regulatory outcomes, IP costs, and market competition. No specific revenue guidance; focus on milestones from Ultragenyx, Novartis agreements.